Technical Analysis for AGEN - Agenus Inc.
|Grade||Last Price||% Change||Price Change|
AGEN closed up 1.12 percent on Monday, August 21, 2017, on 45 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Trend Table & Recent Alerts
|See historical AGEN trend table...|
|Date||Alert Name||Type||% Chg|
|Aug 21||NR7||Range Contraction||0.00%|
|Aug 21||NR7-2||Range Contraction||0.00%|
|Aug 21||Narrow Range Bar||Range Contraction||0.00%|
|Aug 18||NR7||Range Contraction||1.12%|
|Aug 18||Narrow Range Bar||Range Contraction||1.12%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AGEN news...
|52 Week High||7.49|
|52 Week Low||3.2|
|200-Day Moving Average||4.0255|
|50-Day Moving Average||4.1011|
|20-Day Moving Average||4.0323|
|10-Day Moving Average||3.635|
|Average True Range||0.2447|
|Chandelier Exit (Long, 3 ATRs)||4.7159|
|Chandelier Exit (Short, 3 ATRs)||4.1541|
|Upper Bollinger Band||5.0521|
|Lower Bollinger Band||3.0125|
|Percent B (%b)||0.29|
|MACD Signal Line||-0.1545|